List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4938866/publications.pdf Version: 2024-02-01



TEDESA RAMDINO

#	Article	IF	CITATIONS
1	Renal Outcomes of Dialysis-Dependent Acute Kidney Injury in Noncritically Ill Patients: A Retrospective Study. Blood Purification, 2022, 51, 390-396.	1.8	2
2	The innate immune system in human kidney inflammaging. Journal of Nephrology, 2022, 35, 381-395.	2.0	21
3	Extracellular Vesicles Derived from Mesenchymal Stromal Cells Delivered during Hypothermic Oxygenated Machine Perfusion Repair Ischemic/Reperfusion Damage of Kidneys from Extended Criteria Donors. Biology, 2022, 11, 350.	2.8	16
4	Effect of a Third Dose of SARS-CoV-2 mRNA BNT162b2 Vaccine on Humoral and Cellular Responses and Serum Anti-HLA Antibodies in Kidney Transplant Recipients. Vaccines, 2022, 10, 921.	4.4	21
5	Acute kidney injury caused by COVID-19 in a patient with Crohn's disease treated with adalimumab. Journal of Clinical Pathology, 2021, 74, 540-542.	2.0	5
6	Effects of Different Dialysis Strategies on Inflammatory Cytokine Profile in Maintenance Hemodialysis Patients with COVID-19: A Randomized Trial. Journal of Clinical Medicine, 2021, 10, 1383.	2.4	6
7	MO905EFFECTS OF DIFFERENT DIALYSIS TECHNIQUES ON INFLAMMATION IN MAINTENANCE HEMODIALYSIS PATIENTS WITH COVID-19: A RANDOMIZED STUDY. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
8	Persistent Neutropenia after ABOi Kidney Transplantation: A Case Report. Transplantology, 2021, 2, 183-190.	0.6	0
9	Photopheresis Abates the Anti-HLA Antibody Titer and Renal Failure Progression in Chronic Antibody-Mediated Rejection. Biology, 2021, 10, 547.	2.8	7
10	Characterization of Varicella-Zoster (VZV) Specific T Cell Response in Healthy Subjects and Transplanted Patients by Using Enzyme Linked Immunospot (ELISpot) Assays. Vaccines, 2021, 9, 875.	4.4	7
11	Cutaneous lymphocytic vasculitis after administration of COVID â€19 mRNA vaccine. Dermatologic Therapy, 2021, 34, e15076.	1.7	17
12	Hemoperfusion with CytoSorb as Adjuvant Therapy in Critically Ill Patients with SARS-CoV2 Pneumonia. Blood Purification, 2021, 50, 566-571.	1.8	49
13	Robust and Persistent B- and T-Cell Responses after COVID-19 in Immunocompetent and Solid Organ Transplant Recipient Patients. Viruses, 2021, 13, 2261.	3.3	10
14	Kidney Transplants From Donors on Extracorporeal Membrane Oxygenation Prior to Death Are Associated With Better Long-Term Renal Function Compared to Donors After Circulatory Death. Transplant International, 2021, 35, 10179.	1.6	8
15	Immune Response to BNT162b2 in Solid Organ Transplant Recipients: Negative Impact of Mycophenolate and High Responsiveness of SARS-CoV-2 Recovered Subjects against Delta Variant. Microorganisms, 2021, 9, 2622.	3.6	9
16	Kidney transplant rejection rate in screened patients for anti-SARS-CoV-2 antibodies, during COVID-19 pandemic in Northern Italy. New Microbiologica, 2021, 44, 184-186.	0.1	0
17	Everolimus in kidney transplant recipients at high cardiovascular risk: a narrative review. Journal of Nephrology, 2020, 33, 69-82.	2.0	8
18	Calcineurin Inhibitor-Based Immunosuppression and COVID-19: Results from a Multidisciplinary Cohort of Patients in Northern Italy. Microorganisms, 2020, 8, 977.	3.6	41

#	Article	IF	CITATIONS
19	Tracheal necrotizing granulomatosis in antineutrophil cytoplasmic antibody–associated vasculitis. Kidney International, 2020, 98, 1624.	5.2	0
20	Kinetics of cytomegalovirus and Epstein-Barr virus DNA in whole blood and plasma of kidney transplant recipients: Implications on management strategies. PLoS ONE, 2020, 15, e0238062.	2.5	16
21	Renal replacement therapy in acute kidney injury. Lancet, The, 2020, 396, 1974.	13.7	3
22	P1600KIDNEY PERFUSION WITH MESENCHYMAL STROMAL CELLS OR EXTRACELLULAR VESICLES PREVENTS ISCHAEMIC DAMAGE THROUGH CD73/ADO SYSTEM IN A RAT MODEL OF DCD DONATION. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
23	COVID-19 and kidney transplantation: an Italian Survey and Consensus. Journal of Nephrology, 2020, 33, 667-680.	2.0	40
24	Myostatin in the Arterial Wall of Patients with End-Stage Renal Disease. Journal of Atherosclerosis and Thrombosis, 2020, 27, 1039-1052.	2.0	8
25	Arterial "inflammaging" drives vascular calcification in children on dialysis. Kidney International, 2019, 96, 522.	5.2	5
26	Under-recognized post-stroke acute kidney injury: risk factors and relevance for stroke outcome of a frequent comorbidity. International Urology and Nephrology, 2019, 51, 1597-1604.	1.4	7
27	Vitamin e-loaded membrane dialyzers reduce hemodialysis inflammaging. BMC Nephrology, 2019, 20, 412.	1.8	20
28	Management of targeted therapies in cancer patients with chronic kidney disease, or on haemodialysis: An Associazione Italiana di Oncologia Medica (AIOM)/Societa' Italiana di Nefrologia (SIN) multidisciplinary consensus position paper. Critical Reviews in Oncology/Hematology, 2019, 140, 39-51.	4.4	11
29	Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet, The, 2019, 393, 1937-1947.	13.7	408
30	Significance of serum Myostatin in hemodialysis patients. BMC Nephrology, 2019, 20, 462.	1.8	9
31	Psychological Aspects and Psychopharmacologic Treatment in the Very Early Period After Kidney Transplantation: Role of a Multidisciplinary Approach. Transplantation Proceedings, 2019, 51, 143-146.	0.6	2
32	Living Kidney Donation Is Recipient Age Sensitive and Has a High Rate of Donor Organ Disqualifications. Transplantation Proceedings, 2019, 51, 120-123.	0.6	3
33	Soluble Toll-like Receptor 4: A New Player inÂSubclinical Inflammation and Malnutrition in Hemodialysis Patients. , 2018, 28, 259-264.		7
34	Rituximab in primary membranous nephropathy: beyond a B-cell-centered paradigm?. Clinical and Experimental Nephrology, 2018, 22, 208-209.	1.6	6
35	Early onset of graft glomerulopathy in a patient with post-transplant diabetes mellitus after renal transplantation: a case report. BMC Nephrology, 2018, 19, 348.	1.8	2
36	High preoperative plasma endothelin-1 levels are associated with increased acute kidney injury risk after pulmonary endarterectomy. Journal of Nephrology, 2018, 31, 881-888.	2.0	4

#	Article	IF	CITATIONS
37	Rhabdomyolysis-Associated Acute Kidney Injury. American Journal of Kidney Diseases, 2018, 71, A12-A14.	1.9	26
38	Human cytomegalovirus (HCMV)â€specific T cell but not neutralizing or IgG binding antibody responses to glycoprotein complexes gB, gHgLgO, and pUL128L correlate with protection against high HCMV viral load reactivation in solidâ€organ transplant recipients. Journal of Medical Virology, 2018, 90, 1620-1628.	5.0	21
39	Comparison of the T-cell response to human cytomegalovirus (HCMV) as detected by cytokine flow cytometry and QuantiFERON-CMV assay in HCMV-seropositive kidney transplant recipients. New Microbiologica, 2018, 41, 195-202.	0.1	4
40	Understanding Bone Damage After Kidney Transplantation: AÂRetrospective Monocentric Cross Sectional Analysis. Transplantation Proceedings, 2017, 49, 650-657.	0.6	16
41	Global Performance Status Score: A New Tool to Assess Physical Performance in Kidney Transplant Patients. Transplantation Proceedings, 2017, 49, 1270-1275.	0.6	2
42	Management of patients with end-stage renal disease undergoing chemotherapy: recommendations of the Associazione Italiana di Oncologia Medica (AIOM) and the Società Italiana di Nefrologia (SIN). ESMO Open, 2017, 2, e000167.	4.5	27
43	Perfusion of isolated rat kidney with Mesenchymal Stromal Cells/Extracellular Vesicles prevents ischaemic injury. Journal of Cellular and Molecular Medicine, 2017, 21, 3381-3393.	3.6	102
44	Modulation of Myostatin/Hepatocyte Growth Factor Balance by Different Hemodialysis Modalities. BioMed Research International, 2017, 2017, 1-5.	1.9	12
45	RBP4: A Culprit for Insulin Resistance in End Stage Renal Disease That Can Be Cleared by Hemodiafiltration. BioMed Research International, 2017, 2017, 1-8.	1.9	7
46	The Living Donor. , 2017, , 41-50.		0
47	Severe cyclophosphamide-related hyponatremia in a patient with acute glomerulonephritis. World Journal of Nephrology, 2017, 6, 217.	2.0	7
48	Assessment of physical performance and quality of life in kidney-transplanted patients: a cross-sectional study. CKJ: Clinical Kidney Journal, 2016, 10, sfw102.	2.9	10
49	Mesenchymal Stromal Cells Prevent Renal Fibrosis in a Rat Model of Unilateral Ureteral Obstruction by Suppressing the Renin-Angiotensin System via HuR. PLoS ONE, 2016, 11, e0148542.	2.5	28
50	Hepatocyte growth factor (HGF) and hemodialysis: physiopathology and clinical implications. Clinical and Experimental Nephrology, 2016, 20, 371-378.	1.6	15
51	Trained breathing-induced oxygenation acutely reverses cardiovascular autonomic dysfunction in patients with type 2 diabetes and renal disease. Acta Diabetologica, 2016, 53, 217-226.	2.5	14
52	SP650GLOBAL PERFORMANCE STATUS SCORE: A NEW TOOL TO ASSESS PHYSICAL PERFORMANCE IN KIDNEY TRANSPLANTED PATIENTS. Nephrology Dialysis Transplantation, 2016, 31, i311-i311.	0.7	0
53	FP776EFFECTS OF DIALYSIS MODALITY ON MYOSTATIN/HGF BALANCE IN REGULAR HD PATIENTS. Nephrology Dialysis Transplantation, 2015, 30, iii337-iii337.	0.7	0
54	Renal involvement in mushroom poisoning: The case of <scp>O</scp> rellanus syndrome. Hemodialysis International, 2015, 19, E1-5.	0.9	9

#	Article	IF	CITATIONS
55	Huge kidneys in a patient with chronic lymphocytic leukaemia. British Journal of Haematology, 2015, 168, 470-470.	2.5	0
56	Sirolimus vs cyclosporine after induction with basiliximab does not promote regulatory T cell expansion in de novo kidney transplantation: Results from a single-center randomized trial. Transplant Immunology, 2015, 33, 117-124.	1.2	13
57	Costimulatory blockade: A novel approach to the treatment of glomerular disease?. World Journal of Methodology, 2015, 5, 20.	3.5	1
58	Mesenchymal stromal cells reset the scatter factor system and cytokine network in experimental kidney transplantation. BMC Immunology, 2014, 15, 44.	2.2	23
59	Costimulatory Pathways in Kidney Transplantation: Pathogenetic Role, Clinical Significance and New Therapeutic Opportunities. International Reviews of Immunology, 2014, 33, 212-233.	3.3	16
60	Management of mineral metabolism in haemodialysis patients: need for new strategies. European Journal of Clinical Nutrition, 2014, 68, 859-860.	2.9	3
61	Management of mineral metabolism in hemodialysis patients: discrepancy between interventions and perceived causes of failure. Journal of Nephrology, 2014, 27, 689-697.	2.0	3
62	Multiple electrolyte disorders in a neurosurgical patient: solving the rebus. BMC Nephrology, 2013, 14, 140.	1.8	2
63	The role of therapeutic drug monitoring in the treatment of cytomegalovirus disease in kidney transplantation. International Urology and Nephrology, 2013, 45, 1809-1813.	1.4	27
64	Ganciclovirâ€resistant cytomegalovirus infection in transplanted patients: utility of drug monitoring. Transplant Infectious Disease, 2013, 15, E122-3.	1.7	2
65	Selective bilirubin removal: a treatment of jaundice-related kidney injury?. Kidney International, 2013, 84, 624-625.	5.2	5
66	Antineutrophil Cytoplasmic Antibody-Associated Renal Vasculitis Treated With Autologous Mesenchymal Stromal Cells: Evaluation of the Contribution of Immune-Mediated Mechanisms. Mayo Clinic Proceedings, 2013, 88, 1174-1179.	3.0	21
67	Acute kidney injury: Effect of hemodialysis membrane on Hgf and recovery of renal function. Clinical Biochemistry, 2013, 46, 103-108.	1.9	7
68	Renal diseases in haemophilic patients: pathogenesis and clinical management. European Journal of Haematology, 2013, 91, 287-294.	2.2	20
69	Clinical Audit Improves Hypertension Control in Hemodialysis Patients. International Journal of Artificial Organs, 2013, 36, 305-313.	1.4	7
70	A retrospective analysis of dermatological lesions in kidney transplant patients. Indian Journal of Medical Research, 2013, 137, 1188-92.	1.0	6
71	A New Simple Classification of Donors Based on Organ Perfusion Including Prior-To-Death Ecmo. Transplantation, 2012, 94, 521.	1.0	0
72	Mechanisms underlying sCD40 production in hemodialysis patients. Cellular Immunology, 2012, 278, 10-15.	3.0	14

#	Article	IF	CITATIONS
73	Early Allograft Calcifications After Kidney Transplantation. Urology, 2012, 79, e44.	1.0	2
74	Soluble CD40 as a modulator of CD40 pathway. Immunology Letters, 2012, 147, 85-86.	2.5	7
75	A Unique Patient Presenting With Concomitant Klinefelter Syndrome, Alport Syndrome, and Craniopharyngioma. Journal of Andrology, 2012, 33, 1155-1159.	2.0	7
76	Massive liver polycystic disease in a kidney transplanted patient. Digestive and Liver Disease, 2012, 44, 623.	0.9	1
77	Erythema nodosum in kidney transplant recipient: a rare complication of pneumonia treatment. Transplant Infectious Disease, 2012, 14, 72-74.	1.7	3
78	Scabies Crustosa in a 61-Year-Old Kidney-Transplanted Patient. Journal of General Internal Medicine, 2012, 27, 257-257.	2.6	6
79	GM-CSF contributes to prompt healing of ecthyma gangrenosum lesions in kidney transplant recipient. Journal of Nephrology, 2012, 25, 137-139.	2.0	11
80	Human cytomegalovirus end-organ disease is associated with high or low systemic viral load in preemptively treated solid-organ transplant recipients. New Microbiologica, 2012, 35, 279-87.	0.1	19
81	Mesenchymal stromal cells improve renal injury in anti-Thy 1 nephritis by modulating inflammatory cytokines and scatter factors. Clinical Science, 2011, 120, 25-36.	4.3	26
82	Impact of seropositivity to Chlamydia pneumoniae and anti-hHSP60 on cardiovascular events in hemodialysis patients. Cell Stress and Chaperones, 2011, 16, 219-224.	2.9	3
83	CD40/SCD40 imbalance in hemodialysis patients. Clinical Biochemistry, 2011, 44, 268-269.	1.9	9
84	Atraumatic Spleen Rupture in Dialyzed Patients: Clinical Report and Review of the Literature. Peritoneal Dialysis International, 2011, 31, 486-492.	2.3	6
85	Autoimmune response to heat shock protein 60 in haemodialysis patients. Journal of Internal Medicine, 2010, 267, 440-440.	6.0	2
86	Mesenchymal Stem Cells Infusion Prevents Acute Cellular Rejection in Rat Kidney Transplantation. Transplantation Proceedings, 2010, 42, 1331-1335.	0.6	58
87	Which Is the Most Suitable and Effective Route of Administration for Mesenchymal Stem Cell-Based Immunomodulation Therapy in Experimental Kidney Transplantation: Endovenous or Arterial?. Transplantation Proceedings, 2010, 42, 1336-1340.	0.6	48
88	Scatter Factors in renal disease: Dr. Jeckyll and Mr. Hyde?. Cytokine and Growth Factor Reviews, 2009, 20, 77-85.	7.2	5
89	Toll-like receptor 4 expression is increased in circulating mononuclear cells of patients with immunoglobulin A nephropathy. Clinical and Experimental Immunology, 2009, 159, 73-81.	2.6	99

#	Article	IF	CITATIONS
91	Severe Symptomatic Hyponatremia During Sibutramine Therapy: A Case Report. American Journal of Kidney Diseases, 2008, 52, 137-139.	1.9	16
92	In Reply to â€~A Possible Mechanism for Severe Symptomatic Hyponatremia During Sibutramine Therapy'. American Journal of Kidney Diseases, 2008, 52, 1198.	1.9	0
93	Intermittent haemodiafiltration in refractory congestive heart failure: BNP and balance of inflammatory cytokines. Nephrology Dialysis Transplantation, 2007, 22, 2013-2019.	0.7	46
94	Neutralization of Macrophage-Stimulating Protein Ameliorates Renal Injury in Anti–Thy 1 Glomerulonephritis. Journal of the American Society of Nephrology: JASN, 2007, 18, 1486-1496.	6.1	21
95	Burnout in health care providers of dialysis service in Northern Italy a multicentre study. Nephrology Dialysis Transplantation, 2007, 22, 2283-2290.	0.7	67
96	The effect of sirolimus- or cyclosporine-based immunosuppression effects on T-cell subsets in vivo. Kidney International, 2007, 72, 114-120.	5.2	16
97	KCNA1 and TRPC6 ion channels and NHE1 exchanger operate the biological outcome of HGF/scatter factor in renal tubular cells. Growth Factors, 2007, 25, 382-391.	1.7	22
98	Activation of PPARÎ <sup>3</sup> enhances in vitro the immunosuppressive effect of cyclosporine on T lymphocytes. Transplant Immunology, 2007, 18, 32-36.	1.2	8
99	Evaluation of cytomegalovirus DNAaemia versus pp65-antigenaemia cutoff for guiding preemptive therapy in transplant recipients: a randomized study. Antiviral Therapy, 2007, 12, 63-72.	1.0	47
100	Monitoring of Human Cytomegalovirus-Specific CD4+and CD8+T-Cell Immunity in Patients Receiving Solid Organ Transplantation. American Journal of Transplantation, 2006, 6, 2356-2364.	4.7	143
101	Hepatocyte growth factor and its receptor Met are induced in crescentic glomerulonephritis. Nephrology Dialysis Transplantation, 2005, 20, 1066-1074.	0.7	17
102	Platelet-Independent defect in hemostasis associated with sirolimus use. Transplantation Proceedings, 2004, 36, 700-702.	0.6	7
103	Peritoneal Dialysis and Epithelial-to-Mesenchymal Transition. New England Journal of Medicine, 2003, 348, 2037-2039.	27.0	5
104	The Ron Proto-oncogene Product Is a Phenotypic Marker of Renal Oncocytoma. American Journal of Surgical Pathology, 2003, 27, 779-785.	3.7	48
105	Lunch-related polyuria. American Journal of Kidney Diseases, 2002, 40, 218-219.	1.9	0
106	Macrophage-Stimulating Protein Is Produced by Tubular Cells and Activates Mesangial Cells. Journal of the American Society of Nephrology: JASN, 2002, 13, 649-657.	6.1	39
107	Hepatocyte Growth Factor/Scatter Factor Released during Peritonitis Is Active on Mesothelial Cells. American Journal of Pathology, 2001, 159, 1275-1285.	3.8	47
108	Polarization of T-helper lymphocytes toward the Th2 phenotype in uremic patients. American Journal of Kidney Diseases, 2001, 38, 286-295.	1.9	78

#	Article	IF	CITATIONS
109	Risk Factors for Chronic Renal Dysfunction in Cardiac Allograft Recipients. Nephron, 2000, 84, 21-28.	1.8	31
110	Reply from the authors. Kidney International, 2000, 58, 462-463.	5.2	0
111	Hepatitis C virus in hemodialysis patients. Kidney International, 2000, 58, 462.	5.2	0
112	Hemodialysis prevents liver disease caused by hepatitis C virus: Role of hepatocyte growth factor. Kidney International, 1999, 56, 2286-2291.	5.2	81
113	Hemodialysis stimulates hepatocyte growth factor release. Kidney International, 1998, 53, 1382-1388.	5.2	40
114	Hepatocyte growth factor protects the liver against hepatitis C virus in patients on regular hemodialysis. Journal of Chemotherapy, 1998, 10, 164-166.	1.5	3
115	Stimulation of Hepatocyte Growth Factor in Human Acute Renal Failure. Nephron, 1998, 80, 41-45.	1.8	26
116	Circulating serum lectins of patients with IgA nephropathy stimulate IL-6 release from mesangial cells Journal of the American Society of Nephrology: JASN, 1997, 8, 208-213.	6.1	20
117	Hemodialysis Related Interleukin-2 Receptor Release by Peripheral Blood Mononuclear Cells. ASAIO Journal, 1996, 42, 60-63.	1.6	0
118	Inflammatory effects of peritoneal dialysis: Evidence of systemic monocyte activation. Kidney International, 1996, 49, 506-511.	5.2	77
119	Hemodialysis Related Interleukin-2 Receptor Release by Peripheral Blood Mononuclear Cells. ASAIO Journal, 1996, 42, 60-63.	1.6	7
120	Prevalence of symptoms in patients with simple renal cysts BMJ: British Medical Journal, 1993, 306, 430-431.	2.3	39
121	Hemodialysis related induction of interleukin-6 production by peripheral blood mononuclear cells. Kidney International, 1992, 42, 320-326.	5.2	72
122	Clearances of Small Solutes in Hemodiafiltration and Paired Filtration Dialysis. , 1989, , 201-203.		0